Articles tagged with Oral Cancer
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers emphasize the need for personalized drug delivery systems that consider tumor biology, location, and patient factors to effectively treat oral cancer. Mucoadhesive films, oral sprays, and injectable hydrogels are promising technologies, but their translation to clinical use depends on practical considerations.
A research team at Case Western Reserve University is developing a non-invasive oral cancer test that can diagnose the disease in minutes. The test uses a simple oral swab and measures the ratio of two naturally occurring peptides, offering a promising alternative to current biopsy methods.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
A multidisciplinary team of Penn researchers has developed a platform that delivers a combination of cancer-fighting therapies to treat oral squamous cell carcinoma. The findings show that the platform significantly reduces tumor burden and extends survival in aggressive, p53-therapy-resistant cancer models.
A review highlights the role of culturally rooted practices in oral squamous cell carcinoma (OSCC) risk across global populations. Culturally sensitive prevention strategies combining education, harm reduction, and community engagement are crucial in reducing OSCC incidence and disparities. Dermatologists can play a key role in early c...
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
A non-invasive brush biopsy test has been validated for accurate oral cancer detection within one hour, potentially sparing over 90% of low-risk patients from unnecessary invasive procedures. The test's performance is comparable to a microbiopsy-based assay, making it a game-changer in oral cancer diagnosis and treatment.
Researchers at IISc discovered that low-frequency ultrasound can selectively target and kill oral cancer cells, while leaving healthy tissues unharmed. This approach uses moderate mechanical forces to damage cancer cells beyond their ability to recover, potentially leading to safer treatment strategies for oral cancer.
Oral squamous cell carcinoma (OSCC) is associated with significant morbidity and mortality due to tumor recurrence, metastasis, and therapeutic resistance. TP53 mutations are strongly linked to advanced tumor stage, lymph node metastasis, therapy resistance, and poor prognosis.
Researchers from The University of Osaka identified a unique genetic pattern in carcinoma cuniculatum, a rare type of oral cancer with slower growth and lower risk of spread. This discovery may lead to improved diagnosis and targeted treatment for this challenging-to-diagnose condition.
Researchers identified four distinct mutational clusters in oral cancers lacking traditional risk factors, with two linked to endogenous processes and unique driver gene mutations. The study suggests a potential role of the oral microbiome in tumor development and highlights opportunities for precision medicine approaches.
Researchers have shown that extracts from bioengineered chewing gum reduce levels of three microbes linked to worse outcomes in oral cancers, including HPV and bacteria Pg and Fn. The findings support the value of advancing these therapies to clinical trials as adjuvants or prophylaxis.
Researchers found that intralesional nivolumab reduced lesion size by an average of 60% and achieved complete pathologic response in 6 patients. The treatment also showed promise in treating high-grade and low-grade dysplasia, with 82.13% of treated lesions remaining cancer-free after 12 months.
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
Researchers at the University of Turku discovered that surface cells of lymphatic vessels in oral cancer contain proteins indicating cell division, strongly predicting disease progression and mortality. Early-stage oral cancers can be identified by changes in these vessels, which may lead to death even with small tumors.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Research suggests that blocking growth factor receptor signaling using cancer drugs may overcome two challenges: managing oral cancer pain and preventing opioid tolerance. This approach could control cancer while addressing pain through a non-opioid, biologically rational approach.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
Researchers at UT Health San Antonio School of Dentistry are studying novel targets and approaches to treat oral squamous cell carcinoma, the most common type of oral cancer. The studies aim to reduce pain management and mucositis in patients undergoing radiotherapy.
A low-cost smartphone imaging system called mDOC combines autofluorescence and white light imaging with machine learning to accurately identify oral lesions requiring specialist referral. The system achieved an area under the ROC curve of 0.778, outperforming dental providers in sensitivity and specificity.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
New research reveals that most people are unaware of the link between human papillomavirus (HPV) and various types of cancer, including cervical, oropharyngeal, anal, vaginal, vulvar, and penile cancers. The study highlights the importance of HPV vaccination in preventing these cancers.
A recent study by researchers at University of California San Diego School found that individuals with cannabis use disorder are more than three times more likely to develop oral cancer within five years. The study highlights the potential long-term health risks associated with problematic cannabis use and emphasizes the need for furth...
A multi-omics study identified three critical genes—HCK, LILRA4, and PPT1—that are closely linked to OSCC risk, immune regulation, and treatment sensitivity. The study highlights how these genes could serve as powerful biomarkers for early detection and personalized treatment.
A newly developed low-cost, handheld intraoral device combines optical diagnostics and image-guided photodynamic therapy to detect and treat early-stage oral cancer. The device shows promising accuracy and effectiveness in detecting PpIX fluorescence and monitoring treatment in real-time.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Researchers discovered that METTL3, an oncogene, regulates the expression of SMAD4 via miR-146a-5p in OSCC. This pathway can potentially have therapeutic implications for treating oral squamous cell carcinoma.
A new study reveals lysine-specific demethylase 1 (LSD1) as a crucial player in oral squamous cell carcinoma (OSCC) initiation. Inhibiting LSD1 in early-stage lesions prevents tumor growth, restores immune function, and halts OSCC progression.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
Researchers have developed a pioneering method that combines atomic force microscopy with artificial intelligence to detect changes in cancer cells at a small scale. This enables more accurate and reliable diagnoses, potentially leading to earlier detection and better treatment outcomes.
Researchers from HKU discover critical molecular changes that drive metastasis to lymph nodes and suppress immune responses, offering promising avenues for new treatment approaches. The study highlights the role of the protein POSTN and TGF-β signaling in tumor progression and immune evasion.
A significant association between high sugar-sweetened beverage intake and oral cavity cancer was found in this study involving nonsmoking women. The findings suggest a low baseline risk of oral cavity cancer in these women, highlighting the need for further research to validate the impact of this association.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
Increasing the spacing between integrin-ECM binding domains on the extracellular matrix can boost the efficiency of ultrasound treatment applied to kill cancer cells. A new study found that this increased spacing triggers myosin forces, pumps more calcium inside, and promotes cell death.
Researchers at University of California San Diego have discovered the transformation process of healthy stem cells to cancer stem cells in oral cancer. By activating YAP and HPV oncogenes, normal stem cells are reprogrammed into cancer cells, leading to early-stage tumor initiation.
A UT Health San Antonio researcher and her biotechnology company partner with the school to develop a breakthrough oral cancer drug, CIDD99. The partnership aims to create effective, less toxic cancer therapies for aggressive cancer types.
A study reveals how oral bacteria influence tumor growth and progression in oral squamous cell carcinoma (OSCC), offering new therapeutic targets. The research highlights the importance of maintaining good oral hygiene to prevent cancer development, with potential implications for other forms of cancer.
A recent study found that U.S. soldiers are 10 times more likely to use nicotine pouches, which can cause serious health issues, compared to the general population. The study analyzed anonymous responses from 1,957 soldiers and found that 23.8% reported using nicotine pouches in the previous 30 days.
Researchers from the Keck School of Medicine of USC found an association between levels of manmade “forever chemicals” in drinking water and certain digestive, endocrine, respiratory, and mouth and throat cancers. The study estimated that PFAS contamination contributes to 6,864 cancer cases per year.
A novel patient-derived organoid library of tongue cancer tissue samples reveals new insights into chemoresistance mechanisms, highlighting the importance of autophagy and cholesterol biosynthesis pathways. The research also identifies potential drug targets for overcoming chemotherapy resistance in tongue cancer.
A pooled analysis of over a dozen studies found that drinking caffeinated coffee daily was associated with a 17% lower risk of head and neck cancer overall. Drinking decaffeinated coffee and tea also showed protective effects, with tea linked to a 29% lower risk of hypopharyngeal cancer.
The AIRCARE Project will introduce AI-powered systems for real-time diagnosis and precision CO2 laser surgery, improving outcomes for UADT cancer patients. The project aims to reduce positive margins, enhance surgical precision and ease of use, transforming quality of life.
New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Researchers at Macquarie University discovered that oral cancer cells use protein interactions to block the immune response, offering new clues for treatment. The study found that a protein called STAT3 and its partner proteins may be involved in pathways that help cancer avoid the immune system.
A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
A study found that men infected with high-risk types of HPV could experience sperm death from oxidative stress, leading to impaired fertility. The researchers also discovered a weakened local immune response in the urogenital tract, which may contribute to these effects.
Researchers used low-cost videoscopes to create high-quality 'oral selfies' for OPSCC screening, demonstrating their feasibility and effectiveness. The study's findings support the potential of these devices as a viable tool for widespread screening in resource-limited settings.
The review explores the progression of oral leukoplakia to oral squamous cell carcinoma, highlighting genetic and epigenomic alterations, as well as sample collection methods for research and diagnosis. Advances in sequencing technologies and single-cell analyses are providing deeper insights into cancer progression.
Early oral cancer detection improves patient outcomes and reduces mortality. Advanced technologies like imaging and AI enhance the accuracy of traditional screening methods.
An interdisciplinary team at MUSC Hollings Cancer Center discovered how P. gingivalis interferes with mitophagy, allowing oral cancer tumors to become resistant to chemotherapy. The study identified the role of fimbriae in attaching to specific proteins on the mitophagic membrane, blocking the chemotherapy drug from its attachment point.
Researchers have developed a urine-based test that detects pieces of DNA fragments released by head and neck tumors, providing a non-invasive alternative to traditional blood-based biomarker tests. The test has been shown to detect cancer recurrences far earlier than would typically happen based on clinical imaging.
Low HPV vaccine uptake among US adults aged 27-45 is a concern, particularly for men and Hispanic individuals. Experts stress the need to address disparities in vaccination rates to prevent cancer cases.